MedTrace Logo

Effects of GnRHa on Ovarian Function Against Chemotherapy-induced-gonadotoxicity

NCT02518191 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 345

Last updated 2021-06-11

Study results available
· View outcomes & findings →

Summary

This prospective randomized controlled study is conducted to analyze the effect of Goserelin on ovarian function in women with breast cancer in China.

Conditions

Interventions

DRUG

GnRHa

3.6mg subcutaneous injection every 28 days.Initiated 1-2 weeks before chemotherapy and ended 4-8 weeks after chemotherapy.

Sponsors & Collaborators

  • Zhejiang Cancer Hospital

    collaborator OTHER

  • Xiangyun Zong

    lead OTHER

Principal Investigators

  • XIANGYUN ZONG, MD, PhD · Shanghai Jiao Tong University affiliated 6th Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
49 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-09-01
Primary Completion
2021-01-12
Completion
2021-01-12

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02518191 on ClinicalTrials.gov